PMID- 12904092
OWN - NLM
STAT- MEDLINE
DCOM- 20031008
LR  - 20191107
IS  - 1474-0338 (Print)
IS  - 1474-0338 (Linking)
VI  - 2
IP  - 4
DP  - 2003 Jul
TI  - Safety and efficacy of disease-modifying antirheumatic agents in rheumatoid 
      arthritis and juvenile rheumatoid arthritis.
PG  - 347-65
AB  - The definition of disease-modifying antirheumatic drugs (DMARDs) has changed 
      dramatically over the last decade. Current expectations of efficacy now include 
      amelioration of signs and symptoms of disease activity as well as slowing, if not 
      complete cessation, of disease progression as evidenced by Xray progression and 
      significant improvement of patient function. Rheumatologists assess the safety 
      profile of these agents more critically in an attempt to increase the 
      risk:benefit profile. Traditional agents, such as methotrexate (MTX), 
      sulfasalazine and leflunomide have provided patients with substantial relief of 
      symptoms and some decrease of X-ray progression but have been hampered by the 
      frequent occurrence of significant adverse events (AEs) and inability to maintain 
      benefit for a prolonged period of time. With the increased understanding of the 
      basic mechanism of the disease process, there has been the introduction of four 
      biological disease-modifying agents introduced into clinical practice which have 
      substantially increased the risk:benefit ratio for patients with various 
      rheumatic diseases.
FAU - Fleischmann, Roy
AU  - Fleischmann R
AD  - University of Texas Southwestern Medical Center at Dallas, St Paul University 
      Hospital, 5939 Harry Hines Boulevard, Suite 400, Dallas, Texas 75235, USA. 
      royfleischmann@radiantresearch.com
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Drug Saf
JT  - Expert opinion on drug safety
JID - 101163027
RN  - 0 (Antirheumatic Agents)
SB  - IM
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Juvenile/drug therapy
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Clinical Trials as Topic
MH  - Disease Progression
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Product Surveillance, Postmarketing
MH  - Risk Assessment
RF  - 205
EDAT- 2003/08/09 05:00
MHDA- 2003/10/09 05:00
CRDT- 2003/08/09 05:00
PHST- 2003/08/09 05:00 [pubmed]
PHST- 2003/10/09 05:00 [medline]
PHST- 2003/08/09 05:00 [entrez]
AID - 10.1517/14740338.2.4.347 [doi]
PST - ppublish
SO  - Expert Opin Drug Saf. 2003 Jul;2(4):347-65. doi: 10.1517/14740338.2.4.347.